• 2018-03-26 Product Information

Marketing Approval Granted for RAPALIMUS GEL 0.2% (mTOR inhibitor), SAKIGAKE Designation & Orphan Drug Designation to Treat Angiofibroma in Tuberous Sclerosis Complex

1. 
2. 一覧へ戻る（英語）
3.